Interestingly, several therapeutic studies that target the PD-1/PD-L1 pathway to improve CTL functions during chronic infections or cancer utilize blocking antibodies against PD-L1 rather than PD-1 [15], but the regulation of PD-L1 expression and its functional relevance for CTL killing is less well understood than that of PD-1. The gene discussed is CD274; the disease is cancer.